Trial Profile
A double-blind, placebo-controlled dose-escalation study of carbamylated monomeric tree pollen drops in patients with a history of allergic rhinoconjunctivitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2018
Price :
$35
*
At a glance
- Drugs Tree pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors Lofarma S.p.A
- 09 Sep 2018 Status changed from recruiting to completed.
- 28 Dec 2017 New trial record